PT - JOURNAL ARTICLE AU - Rogier, Eric AU - Battle, Nastassia AU - Bakari, Catherine AU - Seth, Misago D. AU - Nace, Douglas AU - Herman, Camelia AU - Madebe, Rashid A. AU - Mandara, Celine I. AU - Lyimo, Beatus M. AU - Giesbrecht, David J. AU - Popkin-Hall, Zachary R. AU - Francis, Filbert AU - Mbwambo, Daniel AU - Garimo, Issa AU - Aaron, Sijenunu AU - Lusasi, Abdallah AU - Molteni, Fabrizio AU - Njau, Ritha AU - Cunningham, Jane A. AU - Lazaro, Samwel AU - Mohamed, Ally AU - Juliano, Jonathan J. AU - Bailey, Jeffrey A. AU - Udhayakumar, Venkatachalam AU - Ishengoma, Deus S. TI - <em>Plasmodium falciparum pfhrp2</em> and <em>pfhrp3</em> gene deletions among patients enrolled at 100 health facilities throughout Tanzania: February to July 2021 AID - 10.1101/2023.07.29.23293322 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.29.23293322 4099 - http://medrxiv.org/content/early/2023/08/05/2023.07.29.23293322.short 4100 - http://medrxiv.org/content/early/2023/08/05/2023.07.29.23293322.full AB - Plasmodium falciparum with the histidine rich protein 2 gene (pfhrp2) deleted from its genome can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World Health Organization (WHO) recommends switching to a non-HRP2 RDT for P. falciparum clinical case diagnosis when pfhrp2 deletion prevalence causes ≥ 5% of RDTs to return false negative results. Tanzania is a country of heterogenous P. falciparum transmission, with some regions approaching elimination and others at varying levels of control. In concordance with the current recommended WHO pfhrp2 deletion surveillance strategy, 100 health facilities encompassing 10 regions of Tanzania enrolled malaria-suspected patients between February and July 2021. Of 7,863 persons of all ages enrolled and providing RDT result and blood sample, 3,777 (48.0%) were positive by the national RDT testing for Plasmodium lactate dehydrogenase (pLDH) and/or HRP2. A second RDT testing specifically for the P. falciparum LDH (Pf-pLDH) antigen found 95 persons (2.5% of all RDT positives) were positive, though negative by the national RDT for HRP2, and were selected for pfhrp2 and pfhrp3 (pfhrp2/3) genotyping. Multiplex antigen detection by laboratory bead assay found 135/7,847 (1.7%) of all blood samples positive for Plasmodium antigens but very low or no HRP2, and these were selected for genotyping as well. Of the samples selected for genotyping based on RDT or laboratory multiplex result, 158 were P. falciparum DNA positive, and 140 had sufficient DNA to be genotyped for pfhrp2/3. Most of these (125/140) were found to be pfhrp2+/pfhrp3+, with smaller numbers deleted for only pfhrp2 (n=9) or only pfhrp3 (n=6). No dual pfhrp2/3 deleted parasites were observed. This survey estimated that 0.24% (95% confidence interval: 0.08% to 0.39%) of false-negative HRP2-RDTs for symptomatic persons were due to pfhrp2 deletions in this 2021 Tanzania survey. These data provide evidence for HRP2-based diagnostics as currently accurate for P. falciparum diagnosis in Tanzania.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Bill and Melinda Gates Foundation (Inv. No. 002202).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData is available upon reasonable request to the authors.